Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

This study is ongoing, but not recruiting participants.
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Steven Isakoff, MD, PhD, Massachusetts General Hospital Identifier:
First received: November 5, 2009
Last updated: April 13, 2017
Last verified: April 2017

November 5, 2009
April 13, 2017
November 2009
June 2018   (Final data collection date for primary outcome measure)
  • To determine the objective response rate (ORR) of ABT-888 and temozolomide (TMZ) in metastatic breast cancer. [ Time Frame: 2 years ]
  • To determine Safety and Efficacy in an Expansion Cohort of BRCA1/2 Mutation Carriers. [ Time Frame: 2 years ]
    An expansion cohort of 20 additional patients with BRCA1/2 Deleterious Mutations will be evaluated to further assess safety and efficacy of the combination of ABT888 and Temozolomide in metastatic breast cancer.
To determine the objective response rate (ORR) of ABT-888 and temozolomide (TMZ) in metastatic breast cancer. [ Time Frame: 2 years ]
Complete list of historical versions of study NCT01009788 on Archive Site
  • To further characterize the safety and tolerability of ABT-888 and TMZ in patients with metastatic breast cancer. [ Time Frame: 2 years ]
  • To evaluate progression free survival. [ Time Frame: 5 years ]
  • To evaluate the clinical benefit rate. [ Time Frame: 2 years ]
Same as current
Not Provided
Not Provided
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers

The purpose of this research study is to find out if the combination of ABT-888 and temozolomide is safe and effective in treating patients with metastatic breast cancer. ABT-888 works by obstructing a DNA enzyme called poly (ADP-ribose) polymerase (PARP) which helps repair cancer cells damaged by chemotherapy. By blocking the PARP enzyme, the cancer cells are unable to repair themselves and as a result die. The other drug in this study is temozolomide. Temozolomide is designed to damage DNA in order to prevent cancer cells from reproducing. Because PARP inhibitors, such as ABT-888, prevent cancer cells from repairing their own DNA, they enhance the potential of chemotherapy therapy like temozolomide to induce cell death. The combination of ABT-888 and temozolomide has been used in a clinical trial for treatment of other cancers and information for this research study suggests that the combination may help to inhibit growth in breast cancer.


BRCA CARRIER EXPANSION COHORT: The purpose of the expansion cohort is to further evaluate the activity and safety of this combination in BRCA mutation carriers with metastatic breast cancer.

  • Each treatment cycle lasts 28 days. Participants will be given a supply of ABT-88 in the form of capsules which they will take twice daily on days 1-7 of each cycle. Temozolomide is also in capsule form and will be taken once daily on days 1-5 of each cycle.
  • Participants will come into the clinic on day 1 of each cycle and will have the following tests and procedures performed: physical examination, vital signs and blood tests.
  • On day 15 of cycles 1 and 2 and day 22 of each cycle, participants will have blood work done.
  • An assessment fo the tumor by CT scan of the participants chest, abdomen and pelvis will be done every 2 cycles.
Phase 2
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
  • Breast Cancer
  • Metastatic Breast Cancer
  • BRCA1 Gene Mutation
  • brca2 Gene Mutation
  • Drug: ABT-888
    Capsules taken orally twice a day on days 1-7 of each 28 day cycle
    Other Name: veliparib
  • Drug: temozolomide
    capsules taken orally once a day on days 1 through 5 of a 28 day cycle
    Other Name: TMZ
Experimental: TMZ/ABT888
Combination therapy with temozolomide and veliparib
  • Drug: ABT-888
  • Drug: temozolomide
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
June 2019
June 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed breast cancer that is metastatic (Stage IV) or locally advanced recurrent breast cancer that is unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
  • Measurable disease by RECIST criteria
  • All immunohistochemical subtypes of breast cancer are eligible. HER2 positive breast cancer must have progressed on prior standard HER2 therapy or have a contraindication to anti-HER2 therapy.
  • Must have at least 1 prior chemotherapy regimen for metastatic disease, with no limit on total number of prior therapies.
  • 18 years of age or older
  • Life expectancy of at least 12 weeks
  • ECOG Performance Status of 0, 1, or 2
  • Normal organ and marrow function as outlined in the protocol
  • Archived tissue block or 25 unstained slides (from primary and/or metastatic tumor) if available for correlative exploratory studies. Absence of available tissue will not exclude the subjects from participating.
  • CNS metastases are allowed if they are clinically stable without current evidence of symptomatic progression and do not require steroids, whole brain radiation therapy, or stereotactic radiosurgery. This may include brain metastases not previously treated if they are clinically stable as described above.
  • Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.
  • Women of child-bearing potential must have a negative pregnancy test within 14 days of registration.
  • Patients must be progressing on their current therapy
  • Prior exposure to single agent PARP inhibitor is allowed, but no prior exposure to PARP with a combination of chemotherapy is allowed.

Exclusion Criteria:

  • Participants who have had chemotherapy, biologic therapy, small molecule targeted therapy or radiotherapy within 14 days prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Anti-cancer hormonal therapy must be stopped 24 hours prior to starting study treatment.
  • Participants may not be receiving any other investigational agents.
  • Prior therapy with TMZ is allowed except if participant has a history of allergic reactions attributed to TMZ, or if therapy was discontinued due to intolerance of or toxicity from TMZ.
  • Leptomeningeal disease
  • CNS involvement requiring steroids (except for patients who recently completed brain radiation and are on stable or tapering doses of steroids).
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, recent myocardial infarction, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, or other comorbid condition that investigator believes may compromise participant's safe and effective participation in the trial.
  • Concurrent radiation therapy is not permitted while on study
  • Concurrent anti-cancer therapy is not permitted on study
  • Pregnant and breast feeding women
  • History of uncontrolled seizure disorder
  • Individuals with a history of other malignancies are eligible if they meet the following criteria: a) the other malignancy was treated with curative intent and is deemed by the investigator to be at low risk of recurrence , AND b) a metastatic lesion has been histologically confirmed as breast cancer, c) individuals with the following cancers are eligible if diagnosed and treated: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.


An expansion cohort will have the same eligibility requirements with the following notable exceptions:

  • Patients must have known deleterious mutation of BRCA1/2
  • Prior PARP inhibitor combinations with chemotherapy are allowed
  • Any number of prior therapies is allowed, including first line
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Steven Isakoff, MD, PhD, Massachusetts General Hospital
Steven Isakoff, MD, PhD
  • Dana-Farber Cancer Institute
  • Beth Israel Deaconess Medical Center
  • Abbott
Principal Investigator: Steven Isakoff, MD, PhD Massachusetts General Hospital
Massachusetts General Hospital
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP